SEARCH

SEARCH BY CITATION

References

  • 1
    Vivian EM. Type 2 diabetes: Getting up to speed. Am Druggist 1999; 216: 5663.
  • 2
    Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 10251032.
  • 3
    Fuhlendorff J, Shymko R, Carr RD, Kofod H. Characterization of the binding-sites for the novel anti-hyperglycemic drug, repaglinide. Diabetes 1995; 44: 231A.
  • 4
    Fuhlendorff J. Molecular identification of a specific binding-site (36 kda) for repaglinide. Diabetes 1998; 47: A416.
  • 5
    Tronier B, Marbury TC, Damsbo P. A new oral hypoglycemic agent, repaglinide minimizes risk of hypoglycemia in well-controlled NIDDM patients. Diabetologia 1995; 38: A195A195.
  • 6
    Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obesity 2000; 24: S21S31.
  • 7
    Van Heiningen PN, Hatorp V, Kramer Nielsen K, et al. Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing. Eur J Clin Pharmacol 1999; 55: 521525.
  • 8
    Nielsen KK, Bjornsdottir I, Andersen JV, Thomsen MS, Hansen KT. Pharmacokinetics and metabolism of 14C-repaglinide after a single oral dose to healthy Japanese and Caucasian males. Clin Pharmacol Ther 2001; 69: P88P88.
  • 9
    Guay DR. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 11951204.
  • 10
    Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics and pharmacodynamics of repaglinide. Eur J Clin Pharmacol in press.
  • 11
    Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000; 68: 495500.
  • 12
    Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001; 70: 5865.
  • 13
    Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 20892098.
  • 14
    Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome-P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566575.
  • 15
    Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism – role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 19691979.
  • 16
    Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39: 99116.
  • 17
    Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293: 453459.
  • 18
    Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 238: 434442.
  • 19
    Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metab Disp 2000; 28: 13031310.
  • 20
    Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424432.
  • 21
    Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000; 50: 573580.
  • 22
    Schulz-Utermoehl T, Mountfield RJ, Madsen K, Jørgensen PN, Hansen KT. Selective and potent inhibition of human CYP2C19 activity by a conformationally targeted antipeptide antibody. Drug Metab Dispos 2000; 28: 715717.
  • 23
    Schulz-Utermoehl T, Edwards RJ, Boobis AR. Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens. Drug Metab Dispos 2000; 28: 544551.
  • 24
    Schulz-Utermoehl T, Mountfield RJ, Bywater RP, Madsen K, Jørgensen PN, Hansen KT. Structure-function analysis of human CYP3A4 using a specific proinhibitory antipeptide antibody. Drug Metab Dispos 2000; 28: 718725.
  • 25
    Bauer E, Beschke K, Ebner T, et al. Biotransformation of [14C] repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse. Diabetologia 1997; 40: A326.
  • 26
    Owens DR. Repaglinide. a new short-acting insulinotropic agent for the treatment of Type 2 diabetes. Eur J Clin Invest 1999; 29: 3037.
  • 27
    Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrobial Agents Chemother 1993; 37: 265269.
  • 28
    Novo Nordisk. An open-labelled, randomized, crossover trial evaluating a possible interaction of multiple dosing of rifampicin on a single dose of repaglinide pharmacokinetics and pharmacodynamics in healthy subjects. Novo Nordisk Internal Trial report AGEE-1058, 1999. Data on file.